- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
Janssen Announces Submission of Two Applications to U.S. FDA Seeking Approval of SIMPONI ARIA® (golimumab) for the Treatment of Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis
Submissions demonstrate Janssen’s commitment to developing new options for young patients
Global Advocacy and Communications Effort Launched to Drive Action Against COVID-19 and Stop Future Pandemics
South Africa’s Rugby World Cup Winning Captain Siya Kolisi kickstarts behavior change efforts “For Humankind”; calls on other stars from sports and screen to continue to rally around protective actions, like #MaskingForAFriend
U.S. FDA Approves IMBRUVICA® (ibrutinib) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
Patients ages 70 years or younger who were new to CLL treatment lived longer without disease progression with the IMBRUVICA®-based regimen compared to patients treated with a chemoimmunotherapy regimen
Results from Expert Delphi Consensus Survey on Treatment of Pulmonary Arterial Hypertension (PAH) with Oral Prostacyclin Pathway Agents (PPAs) Published in CHEST Journal
Panel of 19 Physicians Provided Consensus Opinions on Clinical Scenarios in Which They Considered Adding Oral PPAs in Patients with PAH on ERA + PDE-5 Inhibitor Background Therapy
Landmark Phase 3 VOYAGER PAD Study of XARELTO® (rivaroxaban) Plus Aspirin Shows Significant Benefit in Patients with Symptomatic Peripheral Artery Disease (PAD) after Lower-Extremity Revascularization
XARELTO® has the potential to be the first anticoagulant in 20 years[i] to show a benefit in these high-risk patients Two major Phase 3 trials have evaluated XARELTO® vascular dose plus aspirin in treating patients with atherosclerotic disease
Janssen Announces Health Canada Approval of CABENUVA™, the First Long-Acting Regimen for the Treatment of HIV
CABENUVA™ offers adults living with HIV a new once-monthly injectable option for maintaining viral suppression
Janssen Announces Results of Phase 3 Study Demonstrating the Safety and Efficacy of Long-Acting Injectable HIV Treatment Regimen of Rilpivirine And Cabotegravir through 96 Weeks
FLAIR Phase 3 study demonstrated patient satisfaction and preference for the long-acting injectable regimen over daily oral therapy
Janssen Announces 48-week Results of Phase 3b Study Demonstrating the Safety and Efficacy of Long-Acting Injectable HIV Treatment of Rilpivirine and Cabotegravir Administered Every Two Months
ATLAS-2M Phase 3 study demonstrated patient preference over daily oral therapy for the every-two-month administration of the long-acting injectable regimen